Dan Bin's health issue: had a coronary artery stent implanted! Investors' health needs to be taken seriously!

Source: International Investment Bank Research Report

A Full Breakdown of the Surgery Involving Degradable Stent by Dan Bin

1. Core Event Information

  • Parties Involved

    : Dan Bin (a well-known private equity investor; Chairman of Orient Horizon)

  • Procedure Content

    : The coronary angiography was performed personally by Ge Junbo, an academician of the Chinese Academy of Sciences and a leading authority in cardiovascular care, and a bioabsorbable coronary stent was implanted

  • Post-Operative Status

    : The vessel regained patency. The doctors informed him to continue medication for 3 years. The stent can fully degrade, and the vessel returns to a healthy state

  • Publication Date

    : March 31, 2026

2. Key Figures and Technical Background

1. Surgeon: Academician Ge Junbo

  • Academician of the Chinese Academy of Sciences; Director of the Department of Cardiology, Zhongshan Hospital affiliated with Fudan University; a leading figure in domestic cardiovascular interventional therapy

  • Key Achievements:

  • Developed the first domestically owned intellectual property bioabsorbable coated coronary stent in China, breaking foreign monopolies and saving patients over RMB 1 billion in medical costs every year

  • Led the R&D of the domestically produced fully bioabsorbable coronary stent Xinsorb (Xinxing), achieving the “fourth revolution” in coronary intervention—“intervention without implantation”

  • Promoted the widespread adoption of bioabsorbable stent technology in clinical practice in China; he is also one of the world’s top experts in this field

2. Technology: Bioabsorbable Stents (BRS)

  • Principle

    : Using poly-L-lactic acid (PLLA) as the core material. After implantation, within 1 year it provides support force comparable to that of a metal stent. In years 1–3, it gradually degrades into water and carbon dioxide, and is ultimately fully absorbed by the human body

  • Avoids long-term risks of permanent metal stent retention in the vessel (such as thrombosis inside the stent and vessel stiffness)

  • After complete degradation around 3 years, the vessel can restore natural vasomotor function, and subsequent CT and magnetic resonance imaging are not affected

  • Especially suitable for younger and middle-aged patients and those with metal allergies

  • Post-Operative Requirements

    : Strictly follow the doctor’s instructions to take medication (antiplatelets, statins, etc.) for 3 years to ensure the stent degrades smoothly and the vessel repairs, reducing the risk of restenosis

3. Medical Professional Interpretation

  1. The Scientific Validity of “Complete Degradation in 3 Years”

    The degradation period of mainstream bioabsorbable stents is 3–5 years. Clinical data show that: at 3 years, the stent is absorbed by over 70%; at 5 years, complete degradation can be achieved. This matches Dan Bin’s post-operative description and conforms to medical consensus.

  2. Limitations on Applicable Populations

    Bioabsorbable stents are not suitable for all patients with coronary heart disease. Typically, they are used only for patients with relatively simple lesions and moderate vessel diameters among younger and middle-aged groups. For complex lesions, metal stents are still the preferred option.

  3. The Importance of Post-Operative Management

    During the stent degradation period, blood pressure, blood lipids, and blood glucose must be strictly controlled. Continue taking medication and undergo regular follow-ups; otherwise, risks such as in-stent restenosis and thrombosis may occur. This is also the core reason doctors emphasize “sticking to medication for three years.”

4. Extension of the Event

As a well-known domestic investor, Dan Bin’s surgery has drawn market attention to his health condition and investment timing; at the same time, it has once again brought China’s domestically made bioabsorbable stent technology into public view, highlighting the strength of independent innovation in China’s cardiovascular interventional field.

A massive amount of information and precise analysis—on the Sina Finance APP

责任编辑:石秀珍 SF183

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin